Abstract：
Diabetic kidney disease (DKD) is the most devastating complication of diabetes mellitus. Identification of patients at the early stages of progression may reduce the disease burden. The limitation of conventional markers such as serum creatinine and proteinuria intensify the need for novel biomarkers. The traditional paradigm of DKD pathogenesis has expanded to the activation of the immune system and inflammatory pathways. Monocyte chemo-attractant protein-1 (MCP-1) is extensively studied, as a key inflammatory mediator that modulates the development of DKD. Recent evidence supports the diagnostic role of MCP-1 in patients with or without proteinuria in DKD, as well as a significant role in the early prediction and risk stratification of DKD. In this review, we will summarize and update present evidence for MCP-1 for diagnostic ability and predicting the progression of DKD.
摘要：
糖尿病肾病（DKD）是糖尿病最严重的并发症。在进展的早期阶段识别患者可以减少疾病负担。常规标志物如血清肌酐和蛋白尿的局限性加强了对新型生物标志物的需求。DKD发病机制的传统范式已扩展到免疫系统和炎症途径的激活。单核细胞趋化蛋白-1（MCP-1）被广泛研究，作为调节DKD发展的关键炎症介质。最近的证据支持MCP-1在有或没有蛋白尿的DKD患者中的诊断作用，以及在DKD的早期预测和风险分层中的重要作用。在这次审查中,我们将总结和更新MCP-1诊断能力和预测DKD进展的现有证据。
